Fagron’s Acquisition of HiperScan

Poellath advised the shareholder-managers of HiperScan GmbH on the deal. GRUENDELPARTNER advised TGFS.

The Belgian pharmaceutical group Fagron acquired the Dresden-based tech company HiperScan GmbH in April 2022.

The Dresden-based technology company HiperScan is a specialist in near-infrared (NIR) spectroscopy and emerged as a spin-off from the Fraunhofer Institute for Photonic Microsystems (IPMS) in 2006. With the Apo-Ident analysis system, which is specially designed to identify raw materials and is used in over 5,500 pharmacies, HiperScan has become a market leader in this segment in Germany. HiperScan currently employs more than 50 people.

Fagron is a global leader in pharmaceutical manufacturing of personalized medicines, focused on providing personalized medicine to hospitals, pharmacies, clinics and patients in 35 countries around the world.

As part of the Fagron family, Hiperscan can now establish its breakthrough material analysis technology on a global scale.

The Poellath team included Andreas Kühnert (Picture – counsel, lead, M&A, venture capital, Munich) and Adalbert Makos (counsel, M&A, venture capital, Munich).

The GRUENDELPARTNER team included Dr. Steffen Fritzsche and Dr. Franziska Beier (beide Corporate / M&A, beide Leipzig).

Involved fees earner: Franziska Beier – Gruendelpartner; Steffen Fritzsche – Gruendelpartner; Andreas Kühnert – P+P Pöllath + Partners; Adalbert Makos – P+P Pöllath + Partners;

Law Firms: Gruendelpartner; P+P Pöllath + Partners;

Clients: HiperScan GmbH ; Technologiegründerfonds Sachsen (TGFS);

Federica Tiefenthaler

Author: Federica Tiefenthaler